Form 4: Director Acquires NAMS Shares & Options

NewAmsterdam Pharma Director Adele M. Gulfo acquired 3,400 restricted stock units and 15,300 stock options on January 7, 2026.

Summary

• Adele M. Gulfo, a Director of NewAmsterdam Pharma Co N.V. (NAMS), acquired 3,400 Ordinary Shares in the form of Restricted Stock Units (RSUs) on January 7, 2026.
• These RSUs were granted for no consideration and will vest on January 7, 2027, subject to continued service.
• Following this transaction, Adele M. Gulfo directly beneficially owns 14,260 Ordinary Shares.
• Additionally, Adele M. Gulfo acquired 15,300 stock options on January 7, 2026, with an exercise price of $35.45 per share.
• These options were granted for no consideration and will vest on January 2, 2027, subject to continued service.
• The acquired stock options have an expiration date of January 7, 2036.
• Following this transaction, Adele M. Gulfo directly beneficially owns 15,300 derivative securities (options).

Sentiment

Score: 7

Explanation: The acquisition of equity by a director, particularly through grants of RSUs and stock options, generally indicates management's alignment with shareholder interests and potential confidence in the company's long-term prospects. This is a positive signal, though typical for compensation.

Positives

• A director's acquisition of both restricted stock units and stock options aligns their interests with shareholders, potentially signaling confidence in the company's future performance.
• The grants of RSUs and options serve as incentives for the director's continued service and contribution to the company's long-term success.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance regarding the company's future performance, but the equity grants are tied to future service and performance.

Industry Context

This filing is a standard disclosure of an insider transaction, common in publicly traded companies, particularly in the pharmaceutical sector where equity compensation is a key component of executive and director remuneration.

Stakeholder Impact

• Shareholders: The director's increased equity stake may be viewed positively as it aligns management's financial interests with those of the shareholders, potentially signaling confidence in the company's future value.
• Employees: The equity grants serve as a form of compensation and retention for key personnel, which can indirectly impact employee morale and stability.

Next Steps

• Continued service by Adele M. Gulfo through January 7, 2027, for the RSUs to vest.
• Continued service by Adele M. Gulfo through January 2, 2027, for the stock options to vest.
• Potential exercise of stock options by Adele M. Gulfo at or before the expiration date of January 7, 2036, if the share price exceeds the exercise price of $35.45.

Key Dates

Keywords

NewAmsterdam Pharma, NAMS, Insider Transaction, Form 4, Restricted Stock Units, Stock Options, Director Compensation, Equity Grant